Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, May Daher et al.|Nature Medicine|2024Cited by 452
Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancerYe Li, Hind Rafei|Immunological Reviews|2023Cited by 31